Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LORELY
2024-516929-31-00Phase 2Authorised
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma, sponsored by Humanitas Research Hospital. Primary endpoint: Overall response rate (ORR). Planned start Oct 2024; status: authorised.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on 2024-516929-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516929-31-00.